ArticleProceedings of the National Academy of Sciences of the United States of America2012

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.

Tuoping Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.